Swipe om te navigeren naar een ander artikel
Patient preference information (PPI) have an increasing role in regulatory decision-making, especially in benefit–risk assessment. PPI can also facilitate prioritization of symptoms to treat and inform meaningful selection of clinical trial endpoints. We engaged patients and caregivers to prioritize symptoms of Duchenne and Becker muscular dystrophy (DBMD) and explored preference heterogeneity.
Best–worst scaling (object case) was used to assess priorities across 11 symptoms of DBMD that impact quality of life and for which there is unmet need. Respondents selected the most and least important symptoms to treat among a subset of five. Relative importance scores were estimated for each symptom, and preference heterogeneity was identified using mixed logit and latent class analysis.
Respondents included patients (n = 59) and caregivers (n = 96) affected by DBMD. Results indicated that respondents prioritized “weaker heart pumping” [score = 5.13; 95% CI (4.67, 5.59)] and pulmonary symptoms: “lung infections” [3.15; (2.80, 3.50)] and “weaker ability to cough” [2.65; (2.33, 2.97)] as the most important symptoms to treat and “poor attention span” as the least important symptom to treat [− 5.23; (− 5.93, − 4.54)]. Statistically significant preference heterogeneity existed (p value < 0.001). At least two classes existed with different priorities. Priorities of the majority latent class (80%) reflected the aggregate results, whereas the minority latent class (20%) did not distinguish among pulmonary and other symptoms.
Estimates of the relative importance for symptoms of Duchenne muscular dystrophy indicated that symptoms with direct links to morbidity and mortality were prioritized above other non-skeletal muscle symptoms. Findings suggested the existence of preference heterogeneity for symptoms, which may be related to symptom experience.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Emery, A. E. (2002). The muscular dystrophies. The Lancet, 359(9307), 687–695. CrossRef
Traynor, K. (2017). Deflazacort approved for Duchenne muscular dystrophy. American Journal of Health-System Pharmacy, 74(6), 368. PubMed
Medical Device Innovation Consortium (MDIC). (2015). Patient centered benefit-risk project report: A framework for incorporating information on patient preferences regarding benefit and risk into regulatory assessments of new medical technology. Arlington: Medical Device Innovation Consortium (MDIC). Retrieved November 3, 2017, from http://mdic.org/wp-content/uploads/2015/05/MDIC_PCBR_Framework_Proof5_Web.pdf.
US Food and Drug Administration. (2016) Patient preference information—voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo requests, and inclusion in decision summaries and device labeling: Guidance for industry, food and drug administration staff, and other stakeholders. Silver Spring: Center for Devices and Radiological Health, Center for Biologics Evaluation and Research, Food and Drug Administration. Retrieved November 3, 2017, from https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm446680.pdf.
Whitty, J. A., Stewart, S., Carrington, M. J., Calderone, A., Marwick, T., Horowitz, J. D., et al. (2013). Patient preferences and willingness-to-pay for a home or clinic based program of chronic heart failure management: Findings from the which? trial. PLoS ONE, 8(3), e58347. CrossRefPubMedPubMedCentral
Waschbusch, D. A., Cunningham, C. E., Pelham, W. E. Jr., Rimas, H. L., Greiner, A. R., Gnagy, E. M., et al. (2011). A discrete choice conjoint experiment to evaluate parent preferences for treatment of young, medication naive children with ADHD. Journal of Clinical Child and Adolescent Psychology, 40(4), 546–561. CrossRefPubMedPubMedCentral
US Food and Drug Administration. (2012) Guidance for industry and food and drug administration staff: Factors to consider when making benefit-risk determinations in medical device premarket approval and de novo classifications. Silver Spring: Center for Devices and Radiological Health, Center for Biologics Evaluation and Research, Food and Drug Administration. Retrieved November 3, 2017, from https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm517504.pdf.
Hauber, B. A., Fairchild, A. O., & Johnson, R. F. (2013). Quantifying benefit-risk preferences for medical interventions: An overview of a growing empirical literature. Applied Health Economics and Health Policy, 11(4), 319–329. CrossRef
US Food and Drug Administration. (2018) Duchenne muscular dystrophy and related dystrophinopathies: Developing drugs for treatment Guidance for industry. Silver Spring: Center for Devices and Radiological Health, Center for Biologics Evaluation and Research, Food and Drug Administration. Retrieved March 17, 2018, from https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM450229.pdf.
Peay, H. L., Sheffer, H., & Tibben, A. (2013). Expectations and decision making in clinical trials for Duchenne and Becker muscular dystrophy. In 18th international congress of the world muscle society, Asilomar.
Finn, A., & Louviere, J. J. (1992). Determining the appropriate response to evidence of public concern: The case of food safety. Journal of Public Policy and Marketing, 11(2), 12–25.
Marley, A. A., & Louviere, J. J. (2005). Some probabilistic models of best, worst, and best-worst choices. Journal of Mathematical Psychology, 49(6), 464–480. CrossRef
Mühlbacher, A. C., Kaczynski, A., Zweifel, P., & Johnson, F. R. (2015). Experimental measurement of preferences in health and healthcare using best-worst scaling: An overview. Health Economics Review, 6(1), 1–14.
Flynn, T. N., & Marley, A. (2014). Best-worst scaling: Theory and methods. In S. Hess & A. Daly (Eds.), Handbook of choice modelling (pp. 178–201). Cheltenham: Edward Elgar Publishing Limited.
Kuhfeld, W. (2010). Orthogonal arrays [TS-723]. Cary, NC: SAS.
Youden, W. J. (1940). Experimental designs to increase accuracy of greenhouse studies. Contributions. Boyce Thompson Institute for Plant Research, 11, 219–228.
Youden, W. J. (1937). Use of incomplete block replications in estimating tobacco-mosaic virus. Contributions from Boyce Thompson Institute, 9(1), 41–48.
Hauber, A. B., González, J. M., Groothuis-Oudshoorn, C. G., Prior, T., Marshall, D. A., Cunningham, C. et al. (2016). Statistical methods for the analysis of discrete choice experiments: A report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value in Health, 19(4):300–315. CrossRefPubMed
- Engaging patients and caregivers in prioritizing symptoms impacting quality of life for Duchenne and Becker muscular dystrophy
Ilene L. Hollin
Ellen M. Janssen
John F. P. Bridges
- Springer International Publishing